Skip to main content
Contact Us
Subscribe
E-Edition
43°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
2025 Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Connect Biopharma Holdings Ltd ADR
(NQ:
CNTB
)
1.150
-0.000 (-0.01%)
Streaming Delayed Price
Updated: 10:52 AM EST, Dec 13, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Connect Biopharma Holdings Ltd ADR
< Previous
1
2
3
4
5
6
Next >
David Szekeres, President of Connect Biopharma Holdings Limited (NASDAQ: CNTB), to Present at NobleCon20
November 05, 2024
Via
Investor Brand Network
Attovia Therapeutics Appoints Chief Financial Officer
October 15, 2024
Steven Chan, an accomplished finance leader, joins Attovia as Chief Financial Officer
From
Attovia Therapeutics, Inc.
Via
GlobeNewswire
Connect Biopharma to Participate in the Cantor Fitzgerald Global Healthcare Conference 2024
September 10, 2024
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
Week In Review: EpimAb Sells T-Cell Engager In $635 Million Deal
September 07, 2024
EpimAb Biotherapeutics sold global rights for a clinical-stage asset to Vignette Bio, a San Francisco startup, in a $635 million deal. Meanwhile, Shenzhen TargetRx raised $20 million by selling China...
Via
Talk Markets
Connect Biopharma Reports First Half 2024 Financial Results and Provides Business Update
September 05, 2024
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
Connect Biopharma to Participate in the Leerink Partners I&I and Metabolism Therapeutics Forum
July 01, 2024
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
June 13, 2024
Via
Benzinga
Connect Biopharma Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
June 12, 2024
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
Connect Biopharma Announces New Leadership and Chair of the Board of Directors
June 12, 2024
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
Connect Biopharma Presents Late-Breaking Abstract at the American Thoracic Society 2024 International Conference on the Positive Rademikibart Data from its Global Phase 2b in Patients with Moderate-to-Severe Asthma
May 22, 2024
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
Connect Biopharma to Present a Late-Breaking Abstract at the American Thoracic Society (ATS) 2024 International Conference on the Positive Results from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma
May 07, 2024
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update
April 16, 2024
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
April 03, 2024
Via
Benzinga
Connect Biopharma to Participate in H.C. Wainwright 2ⁿᵈ Annual Autoimmune & Inflammatory Disease Virtual Conference
March 19, 2024
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
February 20, 2024
Via
Benzinga
Connect Biopharma Appoints Industry Veteran James Huang to Board of Directors
February 12, 2024
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
February 02, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
January 23, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
December 29, 2023
Via
Benzinga
Week in Review: SystImmune Out-Licenses Global Rights for ADC to BMS in $8.4 Billion Deal
December 16, 2023
SystImmune, the Seattle arm of Chengdu’s Biokin Pharma, out-licensed global rights (ex-China) for a bispecific ADC to Bristol Myers Squibb in a $8.4 billion agreement.
Via
Talk Markets
Why Icosavax Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket
December 12, 2023
Shares of Icosavax, Inc. (NASDAQ: ICVX) rose sharply in pre-market trading after AstraZeneca announced plans to buy Icosavax in a deal valued at up to $1.1 billion.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
December 12, 2023
Checking out the biggest pre-market stock movers for Tuesday is the perfect way to get ready for another busy day of trading!
Via
InvestorPlace
Connect Biopharma Announces Positive Rademikibart Global Phase 2b Topline Results in Adult Patients with Moderate-to-Severe Persistent Asthma
December 12, 2023
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
December 11, 2023
Via
Benzinga
Connect Biopharma to Announce Top-Line Data from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma on December 12, 2023
December 11, 2023
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
Stonegate Healthcare Partners Releases Report on Transformative Therapies for Pruritus Management
November 30, 2023
Dallas, Texas--(Newsfile Corp. - November 30, 2023) - Stonegate Healthcare Partners is pleased to...
Via
Newsfile
Week In Review: BeiGene Signs $1.3 Billion Deal For Preclinical CDK2 Inhibitor From Boston’s Ensem
November 25, 2023
Beijing’s BeiGene acquired global rights to a preclinical novel cyclin-dependent kinase 2 (CDK2) inhibitor from Boston’s Ensem Therapeutics in a $1.3 billion agreement. Ensem will receive an upfront...
Via
Talk Markets
Why Urban Outfitters Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
November 22, 2023
Shares of Urban Outfitters, Inc. (NASDAQ: URBN) dipped during Wednesday’s session after the company reported third-quarter financial results.
Via
Benzinga
Why Guess? Shares Are Trading Lower By Around 15%; Here Are 20 Stocks Moving Premarket
November 22, 2023
Shares of Guess?, Inc. (NYSE: GES) shares dipped in pre-market trading after the company reported worse-than-expected third-quarter financial results and issued fourth-quarter adjusted EPS guidance...
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
November 22, 2023
Pre-market stock movers are a hot topic on Wednesday as we check out all of the biggest movements happening this morning!
Via
InvestorPlace
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.